DiaSorin has agreed to pay $55.3 million on a debt- and cash-free basis for Siemens Healthineers' microtiter-based ELISA immunodiagnostics business and related intangible and tangible assets. The acquisition, which is expected to close this year, will expand DiaSorin's global commercial presence and provide the company a "significant client base" in Europe, DiaSorin said.
DiaSorin reaches $55.3M deal to acquire Siemens' ELISA business
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.